Funder
United States Agency for International Development
Bill and Melinda Gates Foundation
Subject
Obstetrics and Gynecology,Reproductive Medicine
Reference18 articles.
1. Contraceptive efficacy and safety of DMPA-SC;Jain;Contraception,2004
2. The safety of subcutaneously administered depot medroxyprogesterone acetate (104 mg/0.65 mL): a systematic review;Dragoman;Contraception,2016
3. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density;Kaunitz;Contraception,2009
4. Pharmacia and upjohn,2020
5. U.S. Food and Drug Administration. Depo-subQ Provera 104 (Medroxyprogesterone acetate) injectable suspension new drug application no.: 021583. Center for Drug Evaluation and Research Clinical Pharmacology and Biopharmaceutics Review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021583s000_ClinPharmR.pdf (accessed April 25, 2021).
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献